- Home
- THO vs BBIO Comparison
THO vs BBIO Comparison
Compare THO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THO
- BBIO
- Stock Information
- Founded
- THO 1980
- BBIO 2015
- Country
- THO United States
- BBIO United States
- Employees
- THO N/A
- BBIO N/A
- Industry
- THO Homebuilding
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- THO Industrials
- BBIO Health Care
- Exchange
- THO Nasdaq
- BBIO Nasdaq
- Market Cap
- THO 5.2B
- BBIO 5.6B
- IPO Year
- THO N/A
- BBIO 2019
- Fundamental
- Price
- THO $101.74
- BBIO $33.79
- Analyst Decision
- THO Buy
- BBIO Strong Buy
- Analyst Count
- THO 6
- BBIO 13
- Target Price
- THO $109.40
- BBIO $48.33
- AVG Volume (30 Days)
- THO 575.2K
- BBIO 2.6M
- Earning Date
- THO 03-05-2025
- BBIO 02-20-2025
- Dividend Yield
- THO 1.93%
- BBIO N/A
- EPS Growth
- THO N/A
- BBIO N/A
- EPS
- THO 3.93
- BBIO N/A
- Revenue
- THO $9,685,433,000.00
- BBIO $217,765,000.00
- Revenue This Year
- THO N/A
- BBIO $2,309.33
- Revenue Next Year
- THO $7.45
- BBIO N/A
- P/E Ratio
- THO $25.86
- BBIO N/A
- Revenue Growth
- THO N/A
- BBIO 2209.77
- 52 Week Low
- THO $88.37
- BBIO $21.62
- 52 Week High
- THO $129.31
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- THO 54.97
- BBIO 68.27
- Support Level
- THO $99.66
- BBIO $33.73
- Resistance Level
- THO $99.89
- BBIO $36.24
- Average True Range (ATR)
- THO 3.01
- BBIO 1.55
- MACD
- THO 1.27
- BBIO 0.60
- Stochastic Oscillator
- THO 73.12
- BBIO 72.81
About THO Thor Industries Inc.
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth wheel towables across over 30 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motorcaravans, campervans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts through the acquisition of Airxcel in 2021, however, this is still a nascent part of the business as it accounts for less than 10% of total sales. In fiscal 2023, the company wholesaled 187,015 units and generated over $11.1 billion in revenue.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.